Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edus H Warren

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
British Journal of Haematology|October 10, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphomaRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
JCO Global Oncology|April 4, 2025
Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in UgandaManoj P Menon, Henry Ddungu, Kelvin R Mubiru, et al.
Science (New York, N.Y.)|September 9, 2006
An antigen produced by splicing of noncontiguous peptides in the reverse orderEdus H Warren, Nathalie J Vigneron, Marc A Gavin, et al.
Blood|April 25, 2012
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigenSebastian Ochsenreither, Ravindra Majeti, Thomas Schmitt, et al.
JCI Insight|May 24, 2016
Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamideChristopher G Kanakry, David G Coffey, Andrea M H Towlerton, et al.
JCO Oncology Practice|November 18, 2024
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World ExperienceIvan J Huang, Grace T Baek, Jonathan Cohen, et al.
JCO Precision Oncology|July 12, 2021
High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple MyelomaDavid G Coffey, Andrew J Cowan, Bret DeGraaff, et al.
Practical Radiation Oncology|October 5, 2019
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell LymphomaAileen Kim, Philip Stevenson, Ryan D Cassaday, et al.
Blood|February 27, 2008
DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cellsKellie V Rosinski, Nobuharu Fujii, Jeffrey K Mito, et al.
AIDS (London, England)|September 9, 2022
A prospective study of clinical outcomes of HIV-associated and HIV-negative Kaposi sarcoma in UgandaWarren Phipps, Scott V Adams, Peter Mooka, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
British Journal of Haematology|October 10, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphomaRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
JCO Global Oncology|April 4, 2025
Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in UgandaManoj P Menon, Henry Ddungu, Kelvin R Mubiru, et al.
Science (New York, N.Y.)|September 9, 2006
An antigen produced by splicing of noncontiguous peptides in the reverse orderEdus H Warren, Nathalie J Vigneron, Marc A Gavin, et al.
Blood|April 25, 2012
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigenSebastian Ochsenreither, Ravindra Majeti, Thomas Schmitt, et al.
JCI Insight|May 24, 2016
Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamideChristopher G Kanakry, David G Coffey, Andrea M H Towlerton, et al.
JCO Oncology Practice|November 18, 2024
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World ExperienceIvan J Huang, Grace T Baek, Jonathan Cohen, et al.
JCO Precision Oncology|July 12, 2021
High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple MyelomaDavid G Coffey, Andrew J Cowan, Bret DeGraaff, et al.
Practical Radiation Oncology|October 5, 2019
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell LymphomaAileen Kim, Philip Stevenson, Ryan D Cassaday, et al.
Blood|February 27, 2008
DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cellsKellie V Rosinski, Nobuharu Fujii, Jeffrey K Mito, et al.
AIDS (London, England)|September 9, 2022
A prospective study of clinical outcomes of HIV-associated and HIV-negative Kaposi sarcoma in UgandaWarren Phipps, Scott V Adams, Peter Mooka, et al.
Pageof 9